

Symposium | Psychopharmacology : [Symposium 95] Towards Better Patient Treatments in Asia: Based on the Research on Asian Psychotropic Prescription Patterns (REAP)

🏠 Sun. Sep 28, 2025 1:10 PM - 2:40 PM JST | Sun. Sep 28, 2025 4:10 AM - 5:40 AM UTC 🏠 Session Room 4 (Large Hall B)

[Symposium 95] Towards Better Patient Treatments in Asia: Based on the Research on Asian Psychotropic Prescription Patterns (REAP)

Moderator: Takahiro A. Kato (Department of Psychiatry, Hokkaido University Graduate School of Medicine), Shih-Ku Lin (Chang Gung Memorial Hospital)

[SY-95] Towards Better Patient Treatments in Asia: Based on the Research on Asian Psychotropic Prescription Patterns (REAP)

Takahiro A. Kato¹, Shih-Ku Lin², Naotaka Shinfuku³, Seon-Cheol Park⁴, Sim Kang⁵, Yu-Tao Xiang⁶, Sota Kyuragi⁷, Pornjira Pariwatcharakul⁸, Kok Yoon Chee⁹ (1. Hokkaido University (Japan), 2. Chang Gung Memorial Hospital (Taiwan), 3. Kobe University School of Medicine (Japan), 4. Hanyang University Guri Hospital (Korea), 5. National University of Singapore (Singapore), 6. University of Macau (Macau), 7. Kyushu University (Japan), 8. Mahidol University (Thailand), 9. Kuala Lumpur Hospital (Malaysia))

Keywords : pharmacotherapy, culture, polypharmacy, antidepressants, antipsychotics

‘Research on Asian Psychotropic Prescription Patterns (REAP)’ is an organization and one of the largest psychiatry consortiums formed by psychiatrists, pharmacologists, epidemiologists and researchers in Asia in 2001 (Founders: Naotaka Shinfuku (Japan) and Tan Chay Hoon (Singapore)). REAP serves as a strong research platform of Asian psychiatrists and scientists to improve understanding of patient care in Asia. REAP consortium has completed four studies on prescription patterns of antipsychotics in schizophrenia, two surveys on antidepressants use in major depression and two studies on prescription pattern analysis of mood stabilizers in affective disorders. The cumulative research has involved more than 600 psychiatrists, over 100 psychiatric facilities and over 13,500 patient’s data for analysis. More than 100 research papers have been published in international journals. Just recently, the REAP consortium has completed a study on antidepressant prescription patterns and clinical correlates within psychiatry treatment settings in Asia (REAP-AD3), and we would like to introduce the updated outcomes of REAP-AD3 and our previous REAP studies. Brief summary of our symposium is as follows: (Chairpersons: Takahiro A. Kato (Japan) & Shih-Ku Lin (Taiwan)) • Opening Message: Introduction of the REAP History (Naotaka Shinfuku (Japan)) • 21st Century Trend analysis of REAP (Sim Kang (Singapore)) • Network Analysis of REAP Data (Seon-Cheol Park (South Korea)) • Current Trend of Antidepressant Prescription Patterns in Asia: Findings from the REAP-AD3 Study (Sota Kyuragi (Japan)) • Closing Message: Future of the REAP (Takahiro A. Kato (Japan)) The REAP Consortium solicit cooperation of psychiatrists and researchers from all countries in Asia to enlarge the scope of the consortium beyond prescription patterns. These include studying treatment settings and practices in different countries, patient presentations in common psychiatric disorders, family and community care and patterns of use of psychotherapeutic approaches. Together, we believe that the REAP contribute to improve a variety of patient cares in Asia Pacific region.